接受化疗的老年癌症患者的脆弱性和口味变化的异质性:潜伏类分析
概括
接受化疗的老年癌症患者表现出明显的脆弱性和味道变化概况. 识别这些亚型,特别是那些具有高品味变化和脆弱性的亚型,对于有针对性的干预至关重要.
科学领域:
- 在瘤学瘤学.
- 老年病的医生 老年病的医生
- 临床营养学 临床营养学
背景情况:
- 在接受化疗的患者中,口味变化和脆弱性经常同时发生.
- 在这种人群中,口味变化和脆弱性之间的关联和变化存在有限的研究.
研究的目的:
- 在接受化疗的老年癌症患者中识别不同类型的脆弱性和口味变化.
- 探索患者的特征和与这些亚型相关的风险因素.
主要方法:
- 使用隐性类分析 (LCA) 识别患者子组的横截面研究.
- 在已识别的子组中,社会人口统计学和临床特征进行了比较.
- 用多项逻辑回归来确定子组分类的预测因素.
主要成果:
- 确定了三个不同的子组:"中度口味变化和低脆弱性" (27.5%),"低口味变化和中度脆弱性" (29.0%) 和"高口味变化和高脆弱性" (43.5%).
- "高口味变化和高脆弱性"组主要报告了口味变化 (98.9%) 和脆弱性 (54.0%).
- 与高脆弱性/味道变化组相关的因素包括口腔干燥,高血压和超过三次化疗周期.
结论:
- 这些发现为接受化疗的老年人口味变化和脆弱性之间的关系提供了新的见解.
- 识别不同的味道变化和脆弱性的潜在类别可以为癌症幸存者提供个性化干预措施的发展信息.
更多相关视频
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.9K
10:24Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
6.4K
相关概念视频
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Longitudinal Research
12.0K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Kaplan-Meier Approach
195
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
195
